Who are we?

TRACTIVUS emerges as a spin-off from the research group GEMAT (IQS-Ramón Llull University) and IDIBELL (Bellvitge Biomedical Research Institute) in order to avoid bacterial colonization in medical devices.

 

Developing and providing infection-control solutions for long-lasting devices, Tractivus can reduce healthcare-acquired infections. Less infections reduce complications, hospital stays and the use of antibiotics, thus reducing resource allocation and costs for healthcare. Focusing on people, Tractivus provides a tool to improve the work of health professionals and the life quality of patients.

PHOBOSTech technology have been developed over the years as a final solution to the current problems of medical devices. Our cost-effective patented technology allows to create nanostructures on the surface, preventing bacteria attachment and, therefore, bacteria colonization. As a result our devices show higher lifetime, lower associated costs, and no post-implantation problems without adverse effect on the patients.

Tractivus combines the experience of the research groups and a unique solution designed to root out the colonization of the devices through a micro- and nano-structured coating that protects the device from adhesion and bacterial colonization. The team has worked on all aspects of the development: material selection, regulatory strategy, risk reduction, clinical trials, partners, stakeholders... aiming to maximize  the success of both the project and the investors.

logo_B&W.png
  • email
  • LinkedIn - círculo blanco
  • White Twitter Icon
  • White Facebook Icon

+34 932 672 000

 

Via Augusta, 394

Barcelona (08017)

Spain
 

If you want to contact us do not hesitate to call us, send us an email or use our social media.

Follow us!
  • Twitter
  • Icono social LinkedIn

Funded by:

Copyright © 2020 TRACTIVUS SL. All rights reserved.

 | 

 |